Recent Updates
Recently added Catalysts
CTMX Positive Sentiment Score: 70/100

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

Friday, January 12, 2024 1 min read
Key Takeaway: CytomX Therapeutics has announced that its CEO, Sean McCarthy, will participate in a fireside chat at the B. Riley Securities Virtual Annual Oncology Conference scheduled for January 18, 2024. This event provides an opportunity for the company to showcase its advancements in the field of conditionally activated localized biologics to potential investors. The conference is set to enhance CytomX’s presence and engagement within the oncology investment community.

Market Sentiment Analysis

POSITIVE FACTORS

  • CytomX Therapeutics is recognized for its innovative approach in localized biologics.
  • Participating in a prominent investor conference highlights the company's visibility in the oncology sector.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a fireside chat at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 18, 2024 at 1:00 p.m. ET.
To access this event, please reach out to your B. Riley Securities sale representative for a recording of the fireside chat.
About CytomX Therapeutics
SVP, Finance and Accounting
Investor and Media Contact:
Stern Investor Relations
stephanie.ascher@sternir.com

Frequently Asked Questions

When is the CytomX Therapeutics fireside chat?

The fireside chat is on January 18, 2024, at 1:00 p.m. ET.

Who will represent CytomX at the conference?

Sean McCarthy, D.Phil., will represent CytomX Therapeutics.

How can I access the fireside chat recording?

Contact your B. Riley Securities sales representative for access.

What type of company is CytomX Therapeutics?

CytomX is a leader in conditionally activated, localized biologics.

Who should I contact for investor inquiries?

Contact Stephanie Ascher at Stern Investor Relations for inquiries.

Tags: CTMX Viatris Investor Conferences Healthcare CytomX oncology investor conference biologics
Last updated: Jan 12, 2024